SouthernWorldwide.com – A cure for certain types of cancer could be a realistic objective within the next decade, according to a leading figure in the pharmaceutical industry.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, shared his company’s outlook on the future of cancer treatment during the WSJ Leadership Institute CEO Summit held in London recently.
Duato stated that the ambitious goal for the coming 10 years is to “try to eliminate cancer.”
He acknowledged that this is a significant aspiration, but emphasized that considerable progress is already being made in tackling specific cancers.
As an illustration, Duato pointed to multiple myeloma. He noted that the life expectancy for patients with this condition has increased to approximately 10 years, a stark contrast to the “single years” it was previously.
Duato highlighted the development of treatments that harness the patient’s own immune system to combat cancer. He shared inspiring results where patients who had exhausted all other options and were receiving hospice care have achieved remission for over five years following a single administration of these new therapies.
He described the patient reaction to such outcomes as disbelief, given their long history of weekly hospital visits and multiple treatments over many years.
Johnson & Johnson is actively engaged in deepening its understanding of the biological mechanisms driving cancer growth. The company is also focused on developing innovative technologies to effectively address the disease.
Duato expressed confidence that it is “realistic to believe that we are going to cure certain cancers, and some others we’re going to turn into chronic diseases.”
He underscored the pervasive impact of cancer, stating, “Cancer is an important thing – I cannot think about anybody who has not been touched by cancer.” However, he also pointed to numerous other avenues for scientific advancement and for addressing significant societal challenges.
Duato identified dementia as another critical global problem requiring solutions.
He predicted a continued rise in life expectancy, which has seen steady growth over the past century. This increase is expected to be driven by advancements in longevity technologies and healthcare solutions, ultimately enhancing the quality of life for individuals.
Duato also commented on Johnson & Johnson’s optimistic view of artificial intelligence’s role in the future of healthcare, referring to it as a “force multiplier.”
The integration of biomarkers and AI is seen as crucial for enabling earlier diagnoses. Furthermore, these technologies can facilitate more sophisticated and personalized surgical approaches.
Johnson & Johnson recently completed the acquisition of Firefly Bio, a biotechnology firm specializing in drugs designed to enter cancer cells. These drugs are engineered to target specific proteins associated with gene mutations that are notoriously difficult to treat.
